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Correlation of circulating ANGPTL5 
levels with obesity, high sensitivity 
c-reactive protein and oxidized 
low-density lipoprotein in 
adolescents
Maha M. Hammad  1,6, Mohamed Abu-farha  1,6, Abdullah Al-taiar  2, nada Alam-eldin  1, 
Reem Al-Sabah3, Lemia Shaban4, fahd Al-Mulla  5, Jehad Abubaker1* & Abdur Rahman  4*
Angiopoietin-like proteins (AnGptL) is a family of eight members known to play an important role 
in metabolic diseases. Of these, ANGPTL5 is suggested to regulate triglyceride metabolism and is 
increased in obesity and diabetes. However, its role in metabolic diseases in adolescents is not well-
studied. In this study, we tested the hypothesis of a positive association between plasma ANGPTL5, 
and obesity, high sensitivity c-reactive protein (HscRp) and oxidized low-density lipoprotein (ox-
LDL) in adolescents. Adolescents (n = 431; age 11–14 years) were randomly selected from middle 
schools in Kuwait. Obesity was classified by the BMI-for-age based on the WHO growth charts. Plasma 
ANGPTL5, HsCRP, and Ox-LDL were measured using ELISA. The prevalence of overweight and obesity 
was 20.65% and 33.18%, respectively. Mean (SD) plasma ANGPTL5 levels were significantly higher in 
obese, compared with overweight and normal-weight adolescents (23.05 (8.79) vs 18.39 (7.08) ng/mL, 
and 18.26 (6.95) ng/ml, respectively). ANGPTL5 was positively associated with both HsCRP (ρ=0.27, 
p < 0.001) and Ox-LDL (ρ = 0.24, p < 0.001). In Conclusion, ANGPTL5 levels are elevated in obese 
adolescents and are associated with cardiovascular disease risk factors, HscRp and ox-LDL. the use of 
ANGPTL5 as a powerful diagnostic and prognostic tool in obesity and metabolic diseases needs to be 
further evaluated.
Childhood obesity has emerged as a major public health problem worldwide. In Arab states in the Gulf region, 
extremely high prevalence of childhood obesity has been reported1. On a sample of 13, 000 school children each 
year, Kuwait Nutritional Surveillance has consistently reported that more than 45% of school children aged 5–19 
are either overweight or obese2. Similarly, a cross-sectional study conducted on 635 public intermediate school 
children reported that one quarter of the children (25.5%) were overweight and over one third (36.5%) were 
classified as obese3. In-door lifestyle, lack of physical activity and changes in the dietary pattern have been impli-
cated as the underlying causes of childhood obesity in the region. According to the World Health Organization 
(WHO), the worldwide prevalence of obesity nearly tripled between 1975 and 2016 and is expected to double in 
the next 25 years. This highlights the importance of dealing with this epidemic. Given the widespread prevalence 
of obesity and its long-term and short-term complications, one approach to the problem is to focus on the key 
molecular pathways involved in the development of childhood obesity. This would help identify potential bio-
markers that might be used to guide preventive and therapeutic interventions.
1Biochemistry and Molecular Biology Department, Dasman Diabetes Institute, Kuwait City, Kuwait. 2School of 
Community & Environmental Health, College of Health Sciences, Old Dominion University, Norfolk, VA, USA. 
3Department of Community Medicine and Behavioural Sciences, Faculty of Medicine, Kuwait University, Kuwait 
City, Kuwait. 4Department of Food Science and Nutrition, College of Life Sciences, Kuwait University, Kuwait City, 
Kuwait. 5Genetics and Bioinformatics Department, Dasman Diabetes Institute, Kuwait City, Kuwait. 6These authors 
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Angiopoietin-like protein 5 (ANGPTL5) is a member of the angiopoietin-like proteins (ANGPTLs) family. 
Eight members have been described so far (ANGPTL1 through ANGPTL8), and have been shown to have var-
ious physiological functions in lipid and glucose metabolism, inflammation, hematopoiesis, angiogenesis and 
cancer4–7. They are also differentially expressed in multiple tissues: for example, while ANGPTL3 is exclusively 
expressed in the liver and kidney, ANGPTL7 is expressed in the eye. Other members such as ANGPTL2 and 
ANGPTL4 are more ubiquitously expressed. ANGPTL5, on the other hand, was mainly shown to be expressed 
in adipose tissue, but it was also detected at lower levels in the heart, ovary, testis and skin5,6,8,9. ANGPTLs were 
thought to be orphan ligands until a study showed that ANGPTL1, 2, 5 and 7 can bind to the immune-inhibitory 
receptor human leukocyte immunoglobulin-like receptor B210.
Our group as well as others investigated the levels of different ANGPTLs in disease conditions in adults and 
demonstrated significant differences and associations between certain ANGPTL proteins and obesity, insulin 
resistance, glucose tolerance and inflammation11–19. However, fewer studies examined these proteins and their 
associations with metabolic diseases in childhood and adolescence. Studies in young participants are crucial as 
their samples are less influenced by disease and lifestyle changes. In addition, some members of the ANGPTL 
family, particularly ANGPTL5 and ANGPTL7 are still understudied.
Many studies have reported changes in circulating levels of ANGPTL family proteins members in obesity and 
diabetes, as well as other metabolic diseases. For example, we have shown that levels of ANGPTL8 (also known as 
betatrophin) were significantly elevated in obese, diabetics and people with metabolic syndrome compared with 
individuals without these conditions14–17. A prospective cohort study investigated the serum levels of ANGPTL8 
and ANGPTL3 in Korean Children20. The authors demonstrated that circulating ANGPTL8 levels were posi-
tively associated with triglycerides (TG), whereas ANGPTL3 levels were associated with fasting insulin and the 
homeostasis model assessment of insulin resistance (HOMA-IR). However, the study reported no differences 
in serum levels of ANGPTL8 or ANGPTL3 between normal-weight and overweight children. Previously, we 
have also shown that ANGPTL8 was positively associated with high sensitivity C-reactive protein (HsCRP), a 
well-established marker for inflammation and cardiovascular diseases (CVD)15. Unlike other ANGPTL proteins, 
the role of ANGPTL5 in developing obesity and metabolic diseases remains mostly unknown.
In this study, we aimed to compare the circulating level of ANGPTL5 between obese, overweight and 
normal-weight adolescents, and to investigate the association between ANGPTL5 and well-established CVD 
risk factors, namely HsCRP and oxidized low-density lipoprotein (Ox-LDL). We hypothesize that, like other 
ANGPTL proteins, plasma ANGPTL5 levels are positively associated with obesity, HsCRP, and Ox-LDL.
Materials and Methods
Study participants. This is a cross-sectional study that was conducted in selected public middle schools 
from the State of Kuwait as previously described21,22. Study participants were adolescent in the age range of 
11–14 years.
Blood collection and biochemical analyses. A sample of 5 mL of venous blood was collected in 
gel-containing tubes (SST II Advance, BD Vacutainer) from each child and was analyzed for glucose, complete 
blood count, iron profile, folate, vitamin B12, 25-hydroxyvitamin D, calcium and parathyroid hormone. All the 
blood tests were conducted in a major secondary care hospital where these tests are routinely performed with 
strict quality control measures.
ELISA measurements for ANGPTL5, HsCRP and Ox-LDL. Plasma was obtained from the collected 
blood after centrifugation, aliquoted and then stored at −80 °C. ANGPTL5 concentrations were determined using 
ELISA kit (Cat. # E4440h; Wuhan EIAAB Science, China) with optimal dilution 1:25, HsCRP concentrations 
were determined using ELISA kit (Cat. # HK369; Hycult Biotech) with optimal dilution 1:1000. Finally, Ox-LDL 
concentrations were determined using ELISA kit (Cat. # K 7810; Immundiagnostik AG, Germany) with optimal 
dilution 1:10. All measurements described above followed the manufacturer’s instructions.
Anthropometric measurements and other covariates. Standing height and bodyweight of the study 
participants were measured in a standardized manner, using digital weight and height scale (Detecto, Webb City, 
MO, USA) with the participants standing erect without shoes and wearing light clothes. Data on socioeconomic 
status and other covariates were collected from the parents through a self-administered questionnaire, and from 
the adolescents using face-to-face interview.
Statistical analysis. BMI-for-age z-scores were calculated using WHO growth charts. Obesity was defined 
as BMI-for-age ≥ +3 Standard Deviation (SD), while overweight was defined as BMI-for-age > +2 SD and 
< +3 SD. All measurements are reported as mean (SD) when the data were normally distributed; otherwise, we 
report median (interquartile range: IQR). Although ANGPTL5 was normally distributed across BMI categories, 
the homogeneity of variance assumption was not met. Hence, we used Kruskal-Wallis test followed by Dunn’s 
test as post hoc analysis using Bonferroni adjustment. We used the same approach for Ox-LDL and HsCRP meas-
urements, as these were not normally distributed. The association between ANGPTL5 and each Ox-LDL and 
HsCRP were depicted graphically and Spearman correlation coefficient was calculated. The association between 
ANGPTL5 and overweight or obesity was evaluated using multinomial logistic regression. First, crude odds ratios 
were calculated, then we adjusted for other factors that showed association with overweight and obesity at 20% 
level of significance. However, only self-reported physical condition that limits physical activity was associated 
with overweight and obesity, while all other covariates were not. Therefore, we adjusted for this factor in addition 
to age group (10 years, 12 years, 13 years). Separate analyses were conducted while fitting ANGPTL5, first as a 
continuous variable and then as a categorical variable. Similar analysis was performed with HsCRP and Ox-LDL. 
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We used Wald test to evaluate the statistical significance in these analyses; associations with p < 0.05 were deemed 
to be significant.
ethics statement. The study was approved by The Ethics Committee at Ministry of Health, Kuwait 
(No: 2015/248), the Ethics Committee of the Health Sciences Centre, Kuwait University (No: DR/EC/2338) 
and the Ethical Review Committee at Dasman Diabetes Institute (RA2017-026). Written informed consent 
was obtained from the parents and verbal ascent was obtained from all the study subjects. We certify that 
the work conducted in this research complies with the ethical standards recommended by the Helsinki 
Declaration.
Results
Description of the study group and obesity in school adolescents. The demographic characteris-
tics of the study group are summarized in Table 1. The mean (SD) age was 12.32 (0.85) years and 197 (45.71%) 
were males. Of the 431 participants, 193 (44.78%) were normal-weight, 89 (20.65%) were overweight, and 143 
(33.18%) were obese. Only 6 participants (1.39%) were underweight and these were included in normal-weight 
category in the analysis below. There was no significant difference in the prevalence of obesity or overweight 
between males and females (p = 0.944).
Plasma ANGPTL5 levels are significantly elevated in obese children. We found a significant differ-
ence in ANGPTL5 levels between obese and normal-weight adolescents, as well as between obese and overweight 
participants (p < 0.001). The mean (SD) levels of ANGPTL5 were 18.39 (7.08) ng/mL, 18.26 (6.95) ng/mL and 
23.05 (8.79) ng/mL in normal-weight, overweight and obese adolescents, respectively (Fig. 1). However, levels 
of ANGPTL5 did not differ between overweight and normal-weight groups (p > 0.05). These results remained 
unchanged when we excluded underweight adolescents (n = 6) or when we stratified the analysis by gender. 
Multinomial logistic regression showed that the odds of obesity and overweight was significantly associated with 
ANGPTL5 in univariable analysis and after adjusting for potential confounders (Table 2). This was particularly 
evident when ANGPTL5 was categorized into tertiles (upper tertile OR [95%CI] = 3.59 [2.32, 5.55]; as compared 
to the lower tertile [reference] p < 0.001; Table 2).
Characteristics








   No formal education up to intermediate school 62 14.69
   Secondary (high school) 108 25.59
   Diploma 87 20.62
   University & above 165 39.10
Mother’s Educationb
   No formal education up to intermediate school 44 10.30
   Secondary (high school) 101 23.65
   Diploma 90 21.08
   University & above 192 44.96
Father’s Incomec (Kuwaiti Dinars)
   Less than 500 36 8.59
   500 to 1000 98 23.39
   1001 to 1500 131 31.26
   1501 to 2000 61 14.56
   More than 2000 52 12.41
   Do not wish to tell 41 9.79
Mother’s Employment Statusd
   Housewife 143 33.81
   Paid employment 208 49.17
   Others 72 17.02
Table 1. Socio-demographic characteristics of 431 adolescents enrolled in the study. aMissing for 9 participants; 
bMissing for 4 participants; cMissing for 12 participants; dMissing for 8 participants.
4Scientific RepoRtS |         (2020) 10:6330  | https://doi.org/10.1038/s41598-020-63076-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
Obese children have significantly higher levels of HsCRP. The median (IQR) levels of HsCRP were 
2.57 (0.89–5.60) µg/mL, 0.77 (0.32–1.56) µg/mL, 0.23 (0.04–0.84) µg/mL in obese, overweight and normal-weight 
participants, respectively (Fig. 2). Post hoc analysis showed significant differences in levels of HsCRP between 
each two groups (normal-weight vs overweight, overweight vs obese and obese vs normal-weight [p < 0.01]). 
These results remained unchanged when we excluded underweight adolescents or stratified the analysis by gen-
der. Multinomial logistic regression showed that the odds of obesity and overweight was significantly associated 
with HsCRP in both univariable and multivariable analyses whether HsCRP was fitted as continuous or categor-
ical factor (Table 2).
plasma ox-LDL levels are not associated with obesity in children. The median (IQR) levels of 
Ox-LDL were 188.15 (88.16–485.66) ng/mL, 242.80 (100.13–554.92) ng/mL and 255.72 (119.05–614.92) ng/mL, 
in obese, overweight and normal-weight participants, respectively. There was no significant difference in the lev-
els of Ox-LDL between the different weight groups (p = 0.101). Multinomial logistic regression analysis showed 
no significant association between Ox-LDL and obesity or overweight, neither in univariable nor in multivariable 
analysis (Table 2).
ANGPTL5 correlates with inflammatory markers. We found a positive correlation between ANGPTL5 
and HsCRP levels (Spearman’s rho = 0.27, p < 0.001; Fig. 3). This remained evident even after stratification by 










ANGPTL5 (ng/mL) 1.00 [0.96,1.03] 1.08[1.05,1.11] <0.001 1.00 [0.97,1.03] 1.08[1.06,1.10] <0.001
ANGPTL5 (categories)
Lower tertile (<16.0 ng/mL) 1[Ref.] 1[Ref.] <0.001 1[Ref.] 1[Ref.] 0.002
Middle tertile (≥16.0 & 
<22.6 ng/mL) 0.72[0.35,1.46] 1.12[0.47,2.71] 0.75[0.36,1.54] 1.13[0.48,2.67]
Upper tertile (≥ 22.6 ng/mL) 1.02[0.53,1.95] 3.59[2.32,5.55] 1.08[0.60,1.98] 3.49[2.25,5.40]
HsCRP (µg/mL) 1.72[1.25,2.38] 2.45[1.77,3.39] <0.001 1.73[1.25,2.40] 2.45[1.77,3.38] <0.001
HsCRP (categories)
Lower tertile (<0.28 µg/mL) 1[Ref.] 1[Ref.] 0.004 1[Ref.] 1[Ref.] 0.005
Middle tertile (≥0.28 & 
<1.54 µg/mL) 5.04[2.47,10.30] 6.99[3.09,15.84] 5.02[2.50,10.11] 7.22[2.79,18.63]
Upper tertile (≥1.54 µg/mL) 5.23[1.90,14.31] 47.07[15.14,146.35] 5.21[1.94,13.98] 48.49[13.49,168.74]
Ox-LDL ng/mL 1.00[1.00–1.00] 1.00[1.00–1.00] 0.319 1.00[1.00–1.00] 1.00[1.00–1.00] 0.353
Ox-LDL (categories)
Lower tertile (≤138 ng/mL) 1[Ref.] 1[Ref.] 0.237 1[Ref.] 1[Ref.] 0.111
Middle tertile (>138 & 
≤406 ng/mL) 1.23 [0.72,2.12] 0.92[0.46,1.81] 1.28 [0.76,2.13] 0.86[0.47,1.58]
Upper tertile (>406 ng/mL) 0.82[0.46,1.45] 0.70[0.39,1.27] 0.86[0.44,1.69] 0.65[0.36,1.19]
Table 2. Association between overweight/obesity and each ANGPTL5, HsCRP and Ox-LDL in univariable and 
multivariable multinomial logistic regression. ANGPTL5: Angiopoietin-like protein 5; AOR: Adjusted odds 
ratio (adjusted for age, self-reported physical condition that limits physical activity); HsCRP: High sensitivity 
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gender. Circulating ANGPTL5 levels were also positively correlated with Ox-LDL levels (Spearman’s rho = 0.24, 
p < 0.001) and this correlation was preserved when the population was stratified into normal-weight (Spearman’s 
rho = 0.27, p < 0.001), overweight (Spearman’s rho = 0.32, p = 0.002), or obese (Spearman’s rho = 0.24, p = 0.005; 
Fig. 4).
Discussion
Childhood obesity presents a major public health challenge due to its main role in the development of cardiovas-
cular diseases and diabetes. One of the main pathways that are dysregulated in cardiovascular diseases and diabe-
tes are the ANGPTL proteins. They have been shown to impact metabolic pathways including lipid and glucose 
metabolism as well as inflammation. Elevated levels of ANGPTL proteins have been linked to obesity, diabetes 
and metabolic syndrome11,13,16,17,19. We recently demonstrated an increase in circulating plasma ANGPTL5 levels 
in obese vs non-obese adults as well as in adults with and without diabetes23. In the current study, we investigated 
the role of ANGPTL5, a less studied member of the ANGPTL protein family, in childhood obesity and its associ-
ation with the metabolic markers HsCRP and Ox-LDL.
Our data showed a significant increase in plasma ANGPTL5 levels in obese children compared with 
normal-weight and overweight children. This finding was further confirmed by multinomial logistic regres-
sion analysis, which showed that adolescents with higher levels of plasma ANGPTL5 were 3.5 times more likely 
Figure 2. Distribution of high sensitivity C-reactive protein (HsCRP) in normal weight, overweight and obese 
adolescents.
Figure 3. Correlation between Angiopoietin-like protein (ANGPTL5) and high sensitivity C-reactive protein 
(HsCRP) in 431 adolescents.
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to be obese after adjusting for multiple potential confounders. The lack of significant difference in the plasma 
ANGPTL5 levels between normal-weight and overweight children may indicate that ANGPTL5 is a late obesity 
marker, and therefore, is not present in higher levels in overweight children. Our findings contrast with the few 
studies that investigated other ANGPTLs family members, namely ANGPTL3 and ANGPTL8 (betatrophin), and 
reported no differences between normal-weight and obese children20,24,25. This suggests that ANGPTL5 could be 
a specific and a more sensitive marker for childhood as well as adult obesity than ANGPTL3 and ANGPTL8. On 
the other hand, this apparent difference could result from the different design of the previous studies, in which 
overweight and obese participants were placed in the same group, and levels of ANGPTLs levels were compared 
with normal-weight children. In our study, the stratification into three categories (normal-weight, overweight 
and obese) allowed us to observe significantly lower levels of ANGPTL5 in overweight subjects compared with 
obese participants. Therefore, any difference in ANGPTL levels between normal-weight and overweight/obese 
children in these studies could have been masked by the overweight group. Another striking difference between 
previous studies and ours is the ethnicity of the study population: while our study subjects were Arabs, previous 
studies were conducted on Asian children. Further studies with larger populations are needed to confirm the role 
of ethnicity in the association between ANGPTL5 and obesity.
Obesity is characterized as a low-grade inflammation condition in which various inflammatory markers are 
increased26–28. HsCRP is a powerful marker for detecting low inflammatory processes and is involved in many 
diseases. It is also regularly used for the diagnosis and prognosis of systemic inflammation29. HsCRP is produced 
in the liver in response to inflammatory signals and cytokines. Elevated CRP levels have been associated with car-
diovascular mortality in adults30, as well as an increased risk of diabetes and insulin resistance in adults, children 
and adolescents31,32. Parallel to the increased plasma ANGPTL5, plasma HsCRP levels were significantly higher 
in obese participants compared with normal-weight and overweight subjects. Multinomial logistic regression 
analysis showed that children with higher levels of HsCRP were 1.7 and 2.4 times more likely to be overweight 
and obese, respectively.
The strong positive association between ANGPTL5 and obesity on one hand, and between HsCRP and obesity 
on the other hand, together with the significant positive correlation between ANGPTL5 and HsCRP, suggest that 
both ANGPTL5 and HsCRP are part of a common pathway involved in the development of obesity. The increase 
in circulating HsCRP levels is thought to be attributed to the infiltration of the expanded adipose tissue by mac-
rophages, which are responsible for the generation of inflammatory signals and the production of cytokines such 
as IL-6. Increased production of inflammatory cytokines subsequently can trigger the production of HsCRP by 
hepatocytes33.
Previous studies have suggested that higher levels of ANGPTL proteins are associated with an increased risk of 
CVD due to their role in regulating key metabolic pathways, such as triglyceride (TG) metabolism. It is possible 
that the increased ANGPTL5 can impact TG metabolism. ANGPTL5 has been previously shown to inhibit TG 
lipolysis alongside ANGPTL3, 4 and 8 through inhibiting the activity of lipoprotein lipase (LPL)4,5,34–38. Studies 
on ANGPTL8 and ANGPTL3 knockout mouse models demonstrated that these ANGPTLs play a key role in the 
metabolic transition between fasting and feeding states39,40. The mechanism of action of ANGPTL8 in the fasted 
and fed state and its interplay with ANGPTL3 and 4 was recently reviewed41. Data from several loss-of-function 
Figure 4. Correlation between Angiopoietin-like protein (ANGPTL5) and Oxidized Low-Density Lipoprotein 



































Spearman's rho=0 .27 ; p<0.001 
Obese 
Spearman's rho=0 .24 ; p=0.005 
I( I( ,cl( 
' 
20 40 60 0 
Overweight 
Spearman 's rho=0.32; p=0.002 
All study participants 
Spearman's rho=0.24 ; p<0.001 
I( I( I( l(IO(l( * * "" 
J"",r-. 
' ' ' ' 
20 40 
Angiopoietin-like protein (ANGPTLS) ng/ml 
60 
7Scientific RepoRtS |         (2020) 10:6330  | https://doi.org/10.1038/s41598-020-63076-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
studies showed that alleles in ANGPTL3, 4 and 5 are associated with lower plasma levels of TG. In addition, 1% 
of the participants in the Dallas Heart Study and 4% of those with plasma TG in the lowest quartile had a rare 
loss-of-function mutation in one of the three genes36. Furthermore, sequencing ANGPTL5 revealed a signifi-
cant excess of non-synonymous variants in the lowest quartile of TG levels compared with the highest quartile. 
Overall, 3 out of the 7 missense mutations in ANGPTL5 associated with a low plasma TG level significantly 
reduced the secretion of ANGPTL5 protein while the wild-type and I233V ANGPTL5 (the allele containing the 
missense mutation found in the high TG group) did not interfere with protein secretion. However, in this study, 
the low level of expression of ANGPTL5 compared to ANGPTL3 and 4, did not allow for studying the effect 
of ANGPTL5 mutations on LPL-mediated hydrolysis of TG36. It has also been challenging to further explore 
the functional role of ANGPTL5 in regulating TG metabolism because of the lack of a mouse ortholog. Taken 
together, the available data suggest a common role for some ANGPTLs, including ANGPTL5, in the metabolism 
of TG. It also seems that these proteins are not functionally redundant since the sequence variations in the differ-
ent genes contribute independently to plasma TG levels. Another potential mechanism through which ANGPTL 
may increase the risk of CVD is the triggering of inflammation and the oxidation of LDL. Inflammation is the 
initiating trigger for CVD. The two well-established CVD risk factor are HsCRP and Ox-LDL. The strong posi-
tive correlation of ANGPTL5 with both known biomarkers for CVD clearly suggests a role for ANGPTL5 in the 
pathogenesis of CVD.
Finally, it is important to acknowledge that several approaches are being developed to target ANGPTLs 
because of their role in TG metabolism. One example is controlling ANGPTL levels by cooling. The ration-
ale behind this approach comes from the many reported beneficial effects of activating brown adipose tissue 
(BAT) stimulated by cold exposure. The first ANGPTL that was shown to be affected by cold exposure was 
ANGPTL442,43. Cold exposure increased ANGPTL4 expression in adipose tissue of mice and increased serum 
ANGPTL4 levels in healthy men. A more recent paper reported that short-term cooling can elevate the levels 
of ANGPTL3, 4 and 8 in the plasma of young healthy lean men; however, in middle-aged men who were over-
weight and had prediabetes, only the levels of ANGPTL4 were increased with no effect on the levels of ANGPTL3 
and 844. Another emerging approach for targeting ANGPTL proteins is the use of monoclonal antibodies and 
antisense oligonucleotides. Despite being at early stages, and still limited to ANGPTL3, 4 and 8, this strategy 
is expected to have significant therapeutic effects on metabolic diseases45. For example, a recent study showed 
that the ANGPTL8 antisense oligonucleotide can improve adipose lipid metabolism and prevent diet-induced 
non-alcoholic fatty liver disease and hepatic insulin resistance in rodents46.
Our study has several strengths. First, to the best of our knowledge, this is the first study investigating the 
association between ANGPTL5 and obesity and biomarkers for CVD in adolescents. Previous studies are all 
based on adult populations, which may not be relevant to childhood and adolescent obesity. Second, our study is 
based on a reasonably large sample size, representative of the Kuwaiti adolescent population. Third, we employed 
several statistical approaches to robustly show the association between ANGPTL5 and obesity. Fourth, the data 
were adjusted for many potential confounding factors. There are, however, several limitations in this study as well. 
First, we were unable to obtain data on insulin resistance and lipid profile of the participants. Given that the orig-
inal study was designed to analyze the association between vitamin D levels and cognitive function, it was neither 
necessary nor logistically possible to obtain fasting blood samples required for insulin resistance and lipid profile 
analyses. As such we could not evaluate the association of ANGPTL5 with plasma TG levels in this population. 
Second, the cross-sectional design of the study did not allow us to establish causality and requires further inves-
tigation to establish the role of ANGPTL5 in the development of obesity and the nature of its association with 
Ox-LDL and HsCRP. Finally, the antibody in the ELISA kit that we used for measuring ANGPTL5 recognizes 
the full proteins and is not specific for a particular fragment of the protein. Various fragments of the ANGPTL5 
protein could display different functions as displayed by ANGPTL3 for example. Whether ANGPTL5 displays 
such fragment-specific effects remains to be investigated.
In conclusion, we have demonstrated that ANGPTL5 and HsCRP were increased in obese adolescents in 
our population. This increase in ANGPTL5 was associated with an increased obesity risk. ANGPTL5 showed 
strong positive correlation with the well-known CVD risk factors HsCRP and Ox-LDL. These findings highlight 
the importance of ANGPTL5 in adolescent obesity and metabolic diseases and highlights the need for further 
studies to characterize the potential use of ANGPTL5 as a powerful diagnostic and prognostic tool for obesity 
and metabolic diseases.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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